MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to
see how well it works in treating young patients with relapsed or refractory solid tumors